1 / 6

Prescribing Antiplatelet Therapy in Nonvalvular Atrial Fibrillation: GARFIELD-AF Registry

Analysis comparing antiplatelet therapy vs. oral anticoagulation in AF patients. Trends in prescription practice observed over time. Not recommended for low stroke risk.

chernandez
Télécharger la présentation

Prescribing Antiplatelet Therapy in Nonvalvular Atrial Fibrillation: GARFIELD-AF Registry

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The prescribing of antiplatelet therapy alone in patients with nonvalvular atrial fibrillation: Results from the GARFIELD-AF registryPurpose: To provide an analysis of patients on APT only compared with those prescribed oral AC lone therapy, at enrolment Freek Verheugt, Dan Atar, A. John Camm, Pantep Angchaisuksiri, Giuseppe Ambrosio, Jean-Pierre Bassand, Frank Cools, John Eikelboom, Martin van Eickels, Toon Wei Lim, Wael Al Mahmeed, Frank Misselwitz, Anthony Cowell, Ajay K. Kakkar for the GARFIELD-AF investigators SUBMITTED TO ESC 2016

  2. Methods • GARFIELD-AF is an international, observational registry of patients with newly diagnosed nonvalvular AF and ≥1 additional investigator-determined stroke risk factor

  3. Patients on APT only and those on oral AC lone therapy • Between Mar 2010–Jul 2015, 39,670 patients were enrolled prospectively into four sequential cohorts (C) of ~10,000 patients each (C1: 2010–1; C2: 2011–3; C3: 2013–4; C4: 2014–5) from 35 countries • 22.0% (8714) of patients received APT only (mostly aspirin) and 50.6% (20,085) oral AC lone therapy • The majority in both treatment groups (APT: 83.0%; AC: 87.1%) had a moderate-to-high risk of stroke (CHA2DS2-VASc score ≥2); <3.0% of low-risk patients (score 0) received either treatment • Compared with patients on AC lone therapy, patients receiving APT only were more frequently of Asian ethnicity (OR 2.14; 95%CI 2.01–2.28) and were more likely to have a history of dementia, vascular disease or bleeding, but were less likely to be elderly • There were 45% fewer patients in C4 than C1 on APT (30.2% vs 16.6%), with a clear trend towards a reduction in APT prescribing relative to AC

  4. Factors associated with prescription of APT alone

  5. Conclusion • APT alone is widely prescribed in patients with AF, although it is no longer recommended by the ESC for patients at low risk of stroke or as a substitute for oral anticoagulation • Since this change in guidance and the advent of non-VKA oral ACs, the prescribing of APT alone in newly diagnosed patients with nonvalvular AF has diminished

More Related